应用蛋白质组学探索2型糖尿病增殖期视网膜病变潜在生物标志物

doi:10.3969/j.issn.1006-7795.2024.03.003

摘要/Abstract

摘要： 目的利用同位素标记相对和绝对定量（isobaric tag for relative and absolute quantification, iTRAQ）蛋白质组学技术，分析糖尿病增殖期视网膜病变（proliferative diabetic retinopathy，PDR）患者与糖尿病无视网膜病变患者（diabetes patients without retina diseases，NDR）之间蛋白表达的差异，寻找PDR的候选血清标志物。方法收集2016年至2017年首都医科大学附属北京同仁医院内分泌科住院的PDR患者21例，以及性别年龄匹配的NDR患者21例。患者血清样本混匀后提取蛋白，采用iTRAQ标记,并进行液相质谱-串联质谱检测（liquid chromatograph-mass spectrometer and mass spectrometer, LC-MS/MS）分析，筛选出差异蛋白行基因本体论（Gene Ontology，GO）数据库功能富集及京都基因与基因组百科全书(Kyoto Encyclopedia of Genes and Genome，KEGG)通路显著性富集分析。对相对定量结果进行独立样本t 检验,通过差异倍数(fold change，FC)和P值判定蛋白表达量变化。结果以差异倍数>1.2倍（上/下调），P值≤0.05为标准，筛选出差异蛋白29个，其中PDR组上调蛋白8个，下调蛋白21个。通过对差异蛋白的GO功能显著性富集分析，结果显示，差异基因的功能可分为生物过程、细胞组分和分子功能三个板块。差异表达基因功能涉及生物调节、细胞组成、细胞代谢过程、细胞结合和催化活性等方面。KEGG通路显著性分析显示，上调最为明显的血管紧张素转换酶（angiotensin converting enzyme，ACE）参与肾素－血管紧张素系统（renin angiotensin system，RAS）、肾素分泌等通路，上调蛋白——胰岛素样生长因子I（insulin like growth factor I，IGF-1）参与HIF-1、FoxO、mTOR、PI3K-Akt和AMPK等多条与代谢相关的信号通路。下调显著的蛋白——肌球蛋白6（myosin-6）参与心肌细胞收缩和信号传导通路。结论采用iTRAQ蛋白质组学分析显示，PDR患者与NDR患者存在多种蛋白表达差异，ACE、IGF-1和Myosin-6有望作为糖尿病视网膜病变候选血清诊断标志物，未来可能为PDR的诊断和治疗提供新的靶点。

关键词: 糖尿病视网膜病变, 血清蛋白质组学, 生物标志物, 液相质谱

Abstract: Objective To identify potential biomarkers of proliferative diabetic retinopathy (PDR) through the difference of protein expression between PDR patients and diabetes patients without retina diseases (NDR) by using isobaric tag for relative and absolute quantification (iTRAQ) proteomics. Methods A total of 42 patients admitted to the Department of Endocrinology, Beijing Tongren Hospital from 2016 to 2017 were recruited, including 21 PDR patients and 21 gender- and age-matched NDR patients. After proteins extraction from patients' serum samples, iTRAQ labeling with liquid chromatograph-mass spectrometer and mass spectrometer (LC-MS/MS) analysis was performed to screen the differential proteins. Gene Ontology (GO）enrichment and Kyoto Encyclopedia of Genes and Genome(KEGG) pathway were analyzed. Comparisons were conducted using independent sample t-tests, to determine the changes in protein expression levels through fold change (FC) and P-values. Results Totally 29 differentially expressed proteins were identified based on a FC>1.2 (up/down) and a P value ≤ 0.05. Among them, 8 proteins were upregulated and 21 proteins were downregulated in the PDR group. GO enrichment analysis showed that the functions of differentially expressed genes were classified into three categories: biological processes, cellular components, and molecular functions. The differential gene expressions were involved in biological regulation, cell composition, cellular metabolic processes, and cell binding or catalytic activity. KEGG pathway analysis showed that the most significantly upregulated angiotensin converting enzyme (ACE) is involved in the renin angiotensin system (RAS) and renin secretion pathways. The upregulated protein insulin like growth factor I (IGF-1) is involved in metabolic related signaling pathways, including HIF-1, FoxO, mTOR, PI3K-Akt, and AMPK. The significantly downregulated protein myosin-6 is involved in myocardial cell contraction and signaling pathways. Conclusion The iTRAQ proteomics analysis suggested, many differential expressed proteins between PDR and NDR groups. ACE, IGF-1 and myosin-6 were potential serum diagnostic markers and maybe new therapeutic targets for diabetic retinopathy.

Key words: diabetic retinopathy, serum proteomics, biomarkers, liquid phase mass spectrometry

中图分类号:

R587.1

杨芳远, 彭诗洁, 刘婧, 杨金奎, 朱晓蓉. 应用蛋白质组学探索2型糖尿病增殖期视网膜病变潜在生物标志物[J]. 首都医科大学学报, doi: 10.3969/j.issn.1006-7795.2024.03.003.

Yang Fangyuan, Peng Shijie, Liu Jing, Yang Jinkui, Zhu Xiaorong. To explore the potential biomarkers of proliferative diabetic retinopathy by plasma proteomics[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2024.03.003.

参考文献

［1］Cheung N, Mitchell P, Wong T Y. Diabetic retinopathy［J］. Lancet, 2010, 376(9735): 124－136.
［2］American Diabetes Association. 10. Microvascular complications and foot care: standards of medical care in diabetes-2018［J］. Diabetes Care, 2018, 41(Suppl 1): S105-S118.
［3］Fong D S, Aiello L, Gardner T W, et al. Retinopathy in diabetes［J］. Diabetes Care, 2004, 27 (Suppl 1): S84-S87.
［4］Ting D S W, Cheung G C M, Wong T Y. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review［J］. Clin Exp Ophthalmol, 2016, 44(4): 260－277.
［5］Lachin J M, Genuth S, Nathan D M, et al. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial-revisited［J］. Diabetes, 2008, 57(4): 995－1001.
［6］徐嫚鸿, 李筱荣. 蛋白质组学在糖尿病视网膜病变炎性生物标志物研究中的应用［J］. 中华实验眼科杂志, 2022, 40(9): 869－873.
［7］Kaštelan S, Oreškovic′ I,Bišc′an F, et al. Inflammatory and angiogenic biomarkers in diabetic retinopathy［J］. Biochem Med (Zagreb), 2020, 30(3): 030502.
［8］Youngblood H, Robinson R, Sharma A, et al. Proteomic biomarkers of retinal inflammation in diabetic retinopathy［J］. Int J Mol Sci, 2019, 20(19): 4755.
［9］肖静, 张晓敏, 李筱荣. 糖尿病视网膜病变的蛋白质组学研究进展［J］. 中华眼底病杂志, 2018, 34(4): 407－411.
［10］Angi M, Kalirai H, Coupland S E, et al. Proteomic analyses of the vitreous humour［J］. Mediators Inflamm, 2012, 2012: 148039.
［11］Loukovaara S, Nurkkala H, Tamene F, et al. Quantitative proteomics analysis of vitreous humor from diabetic retinopathy patients［J］. J Proteome Res, 2015, 14(12): 5131－5143.
［12］刘尚清, 张艳艳, 羊惠君, 等. 早期糖尿病大鼠视网膜蛋白质表达变化的初步研究［J］. 眼科研究, 2007, 25(3): 186－189.
［13］Wan T T, Li X F, Sun Y M, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy［J］. Biomed Pharmacother, 2015, 74: 145－147.
［14］Burgos R, Mateo C, Cantón A, et al. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study［J］. Diabetes Care, 2000, 23(1): 80－83.
［15］Fukuda R, Hirota K, Fan F, et al. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells［J］. J Biol Chem, 2002, 277(41): 38205－38211.
［16］Wang W, Lo A C Y. Diabetic retinopathy: pathophysiology and treatments［J］. Int J Mol Sci, 2018, 19(6): 1816.
［17］DeBosch B J, Baur E, Deo B K, et al. Effects of insulin-like growth factor-1 on retinal endothelial cell glucose transport and proliferation［J］. J Neurochem, 2001, 77(4): 1157－1167.
［18］赵世民, 林志光. 肾素－血管紧张素系统与现代医学［M］. 济南: 山东大学出版社, 1995.
［19］Huang K K, Liang Y L, Wang K, et al. Elevated ACE levels indicate diabetic nephropathy progression or companied retina impaired［J］. Front Clin Diabetes Healthc, 2022, 3: 831128.
［20］Letizia C, Repossi P, Sellini M, et al. Serum angiotensin converting enzyme in diabetic retinopathy［J］. Int J Tissue React, 1992, 14: 299－305.
［21］郭志新, 许笑梅, 司兆敏. 血浆内皮素和血清血管紧张素转换酶与糖尿病视网膜病变的关系［J］. 中华眼底病杂志, 1996(3): 39－41.
［22］Otani A, Takagi H, Oh H, et al. Angiotensin Ⅱ-stimulated vascular endothelial growth factor expression in bovine retinal pericytes［J］. Invest Ophthalmol Vis Sci, 2000, 41(5): 1192－1199.
［23］Wang X, Bai Y P, Hong D, et al. Ang Ⅱ induces capillary formation from endothelial cells via the AT1R-dependent inositol requiring enzyme 1 pathway［J］. Biochem Biophys Res Commun, 2013, 434(3): 552－558.
［24］Ola M S, Alhomida A S, Ferrario C M, et al. Role of tissue renin-angiotensin system and the chymase/angiotensin-(1－12) axis in the pathogenesis of diabetic retinopathy［J］. Curr Med Chem, 2017, 24(28): 3104－3114.
［25］Wells A L, Lin A W, Chen L Q, et al. Myosin Ⅵ is an actin-based motor that moves backwards［J］. Nature, 1999, 401(6752): 505－508.
［26］Brown M E, Bridgman P C. Myosin function in nervous and sensory systems［J］. J Neurobiol, 2004, 58(1): 118－130.
［27］Samuels I S, Bell B A, Sturgill-Short G, et al. Myosin 6 is required for iris development and normal function of the outer retina［J］. Invest Ophthalmol Vis Sci, 2013, 54(12): 7223－7233.

[1]	赵苗妙, 李明嘉, 李小亚, 段蕊, 张静宜, 杨金奎. 基于CRISPR/Cas9 技术建立Lepr 与eNos 双基因敲除的糖尿病肾病小鼠模型[J]. 首都医科大学学报, 2024, 45(3): 392-398.
[2]	刘畅, 信中, 杨金奎. 不同性别糖尿病患者饮食质量评分与全因病死率的关系[J]. 首都医科大学学报, 2024, 45(3): 406-412.
[3]	高霞, 胡延晋, 姚志, 王广. 新诊断的2型糖尿病患者血管内皮功能与甲状腺激素敏感性相关性的研究[J]. 首都医科大学学报, 2024, 45(3): 413-419.
[4]	郑晓敏, 刘梦扬, 肖新华, 崔丽梅, 刘翠平. 维生素D₂对糖尿病肾病患者蛋白尿水平的影响[J]. 首都医科大学学报, 2024, 45(3): 420-428.
[5]	张琳, 谢荣荣, 杨芳远, 李眉, 罗莎, 万晓华, 田玮, 杨金奎. 肾小管及肾小球标志物在2型糖尿病患者不同肾损伤阶段诊断价值的研究[J]. 首都医科大学学报, 2024, 45(3): 429-437.
[6]	朱琳, 许永崧, 冯晓彤, 赵冬, 柯静. 糖尿病视网膜病变的药物治疗进展[J]. 首都医科大学学报, 2024, 45(3): 438-445.
[7]	胡亚芬, 华琳. 肠道菌群与糖尿病、炎症因子及C反应蛋白的因果关系——孟德尔随机化分析[J]. 首都医科大学学报, 2024, 45(3): 488-493.
[8]	苏志燕, 刘薇, 史婷婷. 老年2型糖尿病患者血尿酸浓度与代谢综合征的相关性分析[J]. 首都医科大学学报, 2023, 44(1): 137-142.
[9]	宋丽敏, 李思源, 李军, 赵会荣, 李佳佳, 王双. 新疆石河子地区绝经后2型糖尿病女性SOST基因联合LRP5基因多态性及突变与骨代谢关系的研究[J]. 首都医科大学学报, 2022, 43(2): 269-274.
[10]	修双玲, 孙丽娜, 穆志静, 付俊玲, 赵蕾. 不同方法校正的肌肉质量与老年2型糖尿病躯体功能的相关性比较[J]. 首都医科大学学报, 2022, 43(2): 284-288.
[11]	姚舒洋, 李小雪, 王淳秀, 张毅. 埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究[J]. 首都医科大学学报, 2022, 43(2): 289-293.
[12]	李志, 张郡, 戴悦萱, 秦明阳, 梁芙茹. 血糖波动对2型糖尿病大鼠认知功能的影响[J]. 首都医科大学学报, 2021, 42(3): 347-353.
[13]	米颖馨, 王欣, 张开, 李可悦, 孙丽娜, 修双玲. 中老年男性2型糖尿病患者尿酸水平与肌少症的相关性研究[J]. 首都医科大学学报, 2021, 42(3): 453-458.
[14]	郑爽爽, 高志远, 宋双双, 何悦明, 卢洁. BOLD MRI评价糖尿病患者尿微量白蛋白及氧合水平的研究[J]. 首都医科大学学报, 2021, 42(1): 125-130.
[15]	李森, 黄安琪, 郭健飞, 白洁, 张光珍, 王婷, 赵咏梅. 沙格列汀对2型糖尿病患者缺血性脑卒中后认知功能的影响[J]. 首都医科大学学报, 2019, 40(5): 715-720.